Enhancing poxvirus vectors vaccine immunogenicity

Poxvirus-Based Vaccines for Cancer Immunotherapy: New Insights from Combined Cytokines/Co-Stimulatory Molecules Delivery and “Uncommon” Strains

(2014) Valerio Izzi et al.   Anti-Cancer Agents in Medicinal Chemistry

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

(2014) Tomáš Hanke   EXPERT OPINION ON BIOLOGICAL THERAPY

Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens

(2014) J. Garcia-Arriaza et al.   JOURNAL OF VIROLOGY

A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection

(2014) J. Garcia-Arriaza et al.   JOURNAL OF VIROLOGY

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

(2014) Susan Zolla-Pazner et al.   PLoS One

Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen

(2014) Paul F. McKay et al.   PLoS One

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

(2013) Michael A. Morse et al.   ANNALS OF SURGERY

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys

(2013) Dan H. Barouch et al.   CELL

Clinical applications of attenuated MVA poxvirus strain

(2013) Carmen Elena Gómez et al.   Expert Review of Vaccines

CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging

(2013) S Parviainen et al.   GENE THERAPY

New vaccinia virus promoter as a potential candidate for future vaccines

(2013) M. Di Pilato et al.   JOURNAL OF GENERAL VIROLOGY

Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity

(2013) G. L. Smith et al.   JOURNAL OF GENERAL VIROLOGY

Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIVmac251 at Challenge Exposure

(2013) M. Vaccari et al.   JOURNAL OF VIROLOGY

Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens

(2013) L. Sanchez-Sampedro et al.   JOURNAL OF VIROLOGY

Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk

(2013) G. G. A. Fouda et al.   JOURNAL OF VIROLOGY

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways

(2013) Juan García-Arriaza et al.   PLoS One

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C

(2013) Beatriz Perdiguero et al.   PLoS One

A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses

(2013) Sonia T. Wennier et al.   PLoS One

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

A Replicating Modified Vaccinia Tiantan Strain Expressing an Avian-Derived Influenza H5N1 Hemagglutinin Induce Broadly Neutralizing Antibodies and Cross-Clade Protective Immunity in Mice

(2013) Haixia Xiao et al.   PLoS One

Oncolytic myxoma virus: The path to clinic

(2013) Winnie M. Chan et al.   VACCINE

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies

(2013) Asisa Volz et al.   VACCINE

Recombinant MVA vaccines: dispelling the myths

(2013) Matthew G. Cottingham et al.   VACCINE

Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects

(2013) Simon J. Draper et al.   VACCINE

Clinical development of Modified Vaccinia virus Ankara vaccines

(2013) Sarah C. Gilbert   VACCINE

Poxvirus vectors

(2013) Joost H.C.M. Kreijtz et al.   VACCINE

Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine

(2013) Mao Isshiki et al.   VACCINE

Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity

(2013) Henning Lauterbach et al.   Frontiers in Immunology

Poxviral vectors for cancer immunotherapy

(2012) Joseph W Kim et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adjuvant-like Effect of Vaccinia Virus 14K Protein: A Case Study with Malaria Vaccine Based on the Circumsporozoite Protein

(2012) A. Vijayan et al.   JOURNAL OF IMMUNOLOGY

Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced With Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC)

(2012) Baldev Vasir et al.   JOURNAL OF IMMUNOTHERAPY

Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice

(2012) C. E. Gomez et al.   JOURNAL OF VIROLOGY

Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques

(2012) D. A. Garber et al.   JOURNAL OF VIROLOGY

Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity

(2012) Arturo Reyes-Sandoval et al.   MOLECULAR THERAPY

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein

(2012) Juliana Falivene et al.   PLoS One

IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality

(2012) Ana María Rodríguez et al.   PLoS One

Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA

(2012) Toritse Orubu et al.   PLoS One

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens

(2012) Silvia Ratto-Kim et al.   PLoS One

A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity

(2012) Laura Pattacini et al.   PLoS One

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens

(2012) Beatriz Perdiguero et al.   PLoS One

Comparison on Virulence and Immunogenicity of Two Recombinant Vaccinia Vaccines, Tian Tan and Guang9 Strains, Expressing the HIV-1 Envelope Gene

(2012) Rong Zhu et al.   PLoS One

Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus

(2012) Amy C. Boyd et al.   VACCINE

Poxvirus vectors as HIV/AIDS vaccines in humans

(2012) Carmen Elena Gómez et al.   Human Vaccines & Immunotherapeutics

Therapeutic vaccination to treat chronic infectious diseases

(2012) Houda Boukhebza et al.   Human Vaccines & Immunotherapeutics

MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer

(2011) Carmen E. Gomez et al.   CURRENT GENE THERAPY

Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors

(2011) Stephen R Walsh et al.   Expert Review of Vaccines

OX40:OX40L axis: emerging targets for improving poxvirus-based CD8+ T-cell vaccines against respiratory viruses

(2011) John Goulding et al.   IMMUNOLOGICAL REVIEWS

Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults

(2011) J. S. Kennedy et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine

(2011) Lilin Lai et al.   JOURNAL OF INFECTIOUS DISEASES

The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens

(2011) C. E. Gomez et al.   JOURNAL OF VIROLOGY

Expression Profiling of the Intermediate and Late Stages of Poxvirus Replication

(2011) Z. Yang et al.   JOURNAL OF VIROLOGY

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

(2011) Scott G. Hansen et al.   NATURE

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

(2011) Esther D. Quakkelaar et al.   PLoS One

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses

(2011) Juan García-Arriaza et al.   PLoS One

Improved NYVAC-Based Vaccine Vectors

(2011) Karen V. Kibler et al.   PLoS One

Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates

(2011) B. J. Flynn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

(2011) Felipe García et al.   VACCINE

IL-15 increases the frequency of effector memory CD8+ T cells in rhesus monkeys immunized with HIV vaccine

(2010) Shirui Li et al.   Cellular & Molecular Immunology

Highly Persistent and Effective Prime/Boost Regimens against Tuberculosis That Use a Multivalent Modified Vaccine Virus Ankara-Based Tuberculosis Vaccine with Interleukin-15 as a Molecular Adjuvant

(2010) K. Kolibab et al.   Clinical and Vaccine Immunology

Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens

(2010) Magdalini Moutaftsi et al.   Future Microbiology

Prime-boost vectored malaria vaccines: Progress and prospects

(2010) Adrian V. S. Hill et al.   Human vaccines & immunotherapeutics

Immediate-Early Expression of a Recombinant Antigen by Modified Vaccinia Virus Ankara Breaks the Immunodominance of Strong Vector-Specific B8R Antigen in Acute and Memory CD8 T-Cell Responses

(2010) K. Baur et al.   JOURNAL OF VIROLOGY

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

(2010) Sampa Santra et al.   NATURE MEDICINE

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens

(2010) José Luis Nájera et al.   PLoS One

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

(2010) Juan García-Arriaza et al.   PLoS One

Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing

(2010) Z. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poxvirus vector-based HIV vaccines

(2010) Giuseppe Pantaleo et al.   Current Opinion in HIV and AIDS

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model

(2009) J-H Lee et al.   CANCER GENE THERAPY

Correlates of protection efficacy induced by vaccinia virus-specific CD8+T-cell epitopes in the murine intranasal challenge model

(2009) Magdalini Moutaftsi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses

(2009) A. Reyes-Sandoval et al.   INFECTION AND IMMUNITY

Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8

(2009) Tomoya Saito   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vaccinia Virus-Based Multivalent H5N1 Avian Influenza Vaccines Adjuvanted with IL-15 Confer Sterile Cross-Clade Protection in Mice

(2009) L. L. M. Poon et al.   JOURNAL OF IMMUNOLOGY

The Interferon System and Vaccinia Virus Evasion Mechanisms

(2009) Beatriz Perdiguero et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

(2009) Howard L Kaufman et al.   Journal of Translational Medicine

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

(2009) Scott G Hansen et al.   NATURE MEDICINE

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination

(2009) Xiaoxing Huang et al.   PLoS One

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies

(2009) David A. Garber et al.   PLoS One

A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice

(2009) Pin-Yu Perera et al.   VACCINE

Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen

(2009) James W. Hodge et al.   VACCINE

The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine

(2009) Jun Liu et al.   VACCINE

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens

(2009) Carmen E. Gómez et al.   VACCINE

Definition of epitopes and antigens recognized by vaccinia specific immune responses: Their conservation in variola virus sequences, and use as a model system to study complex pathogens

(2009) Alessandro Sette et al.   VACCINE

Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses

(2008) R. Geiben-Lynn et al.   Clinical and Vaccine Immunology

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

(2008) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

(2008) R. Dreicer et al.   INVESTIGATIONAL NEW DRUGS

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunodominance and Recognition of Intracellular Pathogens

(2008) Emma H. Wilson et al.   JOURNAL OF INFECTIOUS DISEASES

Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates

(2008) P. Mooij et al.   JOURNAL OF VIROLOGY

Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes

(2008) E. Assarsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

(2008) Jun Liu et al.   VACCINE

Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes

(2008) Kaifan Dai et al.   VACCINE

EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium

(2008) Pierre-Alexandre Bart et al.   VACCINE

EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

(2008) Sheena McCormack et al.   VACCINE

Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Intra-nasal vaccination

(2007) Sangeetha Vijaysri et al.   VACCINE

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines

(2007) Linda S. Wyatt et al.   VACCINE